Barcelona, Spain, 9th July 2024 – DECISION, an EU-funded research consortium in liver disease research, is pleased to announce the enrollment of the first patient at Hôpital Beaujon, Clichy, France in the COMBAT Trial, a multicenter, randomized, open-label, Phase II clinical trial. This trial is a crucial component of the DECISION project, which aims to transform the treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF).

More information in our Press release.
Watch this video for more information on the COMBAT Trial, a lecture by Prof. Paolo Caraceni, Principal Investigator of the COMBAT Trial.

We’re continuing our series: Some partners of DECISION are currently preparing a special edition in Liver International on acute-on-chronic liver failure (ACLF) and acute decompensation (AD) of cirrhosis! ✨
As a sneak peek, we are excited to share some of the reviews and articles that will be cited in this special edition! (read reviews #1, #2, #3, #4, and #5 here)

The sixth review is:
Shantha R. Valainathan, Qing Xie, Vicente Arroyo, Pierre-Emmanuel Rautou: Prognosis algorithms for acute decompensation of cirrhosis and ACLF. Liver Int 2024.

🔓https://onlinelibrary.wiley.com/doi/10.1111/liv.15927

🔑 Key points

• CLIF-C AD score is a score developed and validated for patients with acute decompensation of cirrhosis without ACLF.
• For patients with ACLF, three different scoring system are widely used, namely the CLIF-C ACLF score, the AARC score and the NACSELD score.
• Predictive value of currently available scores can still be improved.
• Multiomics analyses may help develop novel tools to improve prediction of patients outcome.